Table 7

Angiotensin receptor blocker (ARB) trials in post-myocardial infarction patients: hypotheses tested

		Non-inferiority			Superiority
		ARB ⩽ ACE-I			ARB > ACE-I	ARB + ACE-I > ACE-I
OPTIMAAL	Yes^7-150			Yes^7-151 ( 20%, P 96%)	No

VALIANT	Yes ( 2.5%, P 88%) ( 0%, P 74%)			Yes ( 17.5%, P 95%) ( 15%, P 86%)	Yes ( 17.5%, P 95%) ( 15%, P 86%)

P, power—that is, power of study to detect that risk reduction.
⩽, Not significantly inferior to;
↵7-150 revision of protocol as published^w27—further details not available;
↵7-151 assuming a captopril group annual mortality of 17%.